期刊： ENDOCRINE PATHOLOGY, 2022; 33 (2)
We report two pituitary neuroendocrine tumors (PitNETs) with very high Ki67 labeling indices, many mitoses and TP53 mutation (nearly all tumor cell nu......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (4)
Neoplastic cells acquire the ability to proliferate endlessly by maintaining telomeres via telomerase, or alternative lengthening of telomeres (ALT). ......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (1)
This review of the familial tumor syndromes involving the endocrine organs is focused on discussing the main updates on the upcoming fifth edition of ......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (4)
In cytologically indeterminate thyroid nodules undergoing molecular testing, estimated risk of malignancy is variable. Identification of a non-cancer-......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (3)
Primary ovarian neuroendocrine neoplasms (Ov-NENs) are infrequent and mainly represented by well-differentiated forms (neuroendocrine tumors - NETs - ......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (1)
The 2022 WHO classification reflects increases in the knowledge of the underlying pathogenesis of parathyroid disease. In addition to the classic char......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (2)
Molecular characterization of adrenocortical carcinomas (ACC) by The Cancer Genome Atlas (TCGA) has highlighted a high prevalence of TERT alterations,......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (1)
This review summarizes the classification of tumors of the adrenal medulla and extra-adrenal paraganglia as outlined in the 5th series of the WHO Clas......
期刊： ENDOCRINE PATHOLOGY, 2022; 33 (4)
Some pediatric papillary thyroid carcinoma (PPTC) cohorts have suggested a preliminary correlation with respect to DICER1 mutation status and histomor......
